
    
      sEphB4-HSA will be given through an intravenous infusion (into a vein). Each cycle of
      sEphB4-HSA will be 28 days (4 weeks). Each cycle of the study drug includes administration of
      2 doses of sEphB4-HSA given on Days 1 and 15 of each cycle.

      Participants may continue on study protocol as long as their KS is continuing to respond or
      is clinically stable on study medication.

      Patients may come off treatment for the following reasons:

        -  Disease progression.

        -  Need for more than 2 dose reductions for toxicity.

        -  Dose delay more than 28 days.

        -  Patient withdraws consent.

        -  Study termination by the Sponsor.

        -  Participants who are noncompliant with respect to taking drugs, keeping appointments, or
           having tests required for the evaluation of drug safety and efficacy.

        -  Participant's condition renders them unacceptable for further treatment in the judgment
           of the investigator.
    
  